Blood pressure and the cystic fibrosis gene: Evidence for lower pressure rises with age in female carriers

Hypertension

Volumn 44, Issue 6, 2004, Pages 878-883

  Super, Maurice ^a   Irtiza Ali, Ayesha ^b   Roberts, Stephen A ^c   Schwarz, Martin ^a   Young, Michele ^a   Smith, Alison ^a   Roberts, Theresa ^a   Hinks, Joanna ^a   Heagerty, Anthony ^b  

^a ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Blood pressure; DNA; Mutation; Women

Indexed keywords

CHLORIDE; SODIUM;

ADULT; AGE DISTRIBUTION; ARTICLE; BLOOD PRESSURE MONITORING; CHLORIDE BLOOD LEVEL; CONTROLLED STUDY; CYSTIC FIBROSIS; DIASTOLIC BLOOD PRESSURE; ESSENTIAL HYPERTENSION; FEMALE; GENE; GENE MUTATION; HEART DISEASE; HETEROZYGOTE; HUMAN; HYPOTENSION; PRIORITY JOURNAL; SEX ROLE; SODIUM BLOOD LEVEL; STATISTICAL SIGNIFICANCE; STROKE; SWEAT; SYSTOLIC BLOOD PRESSURE;

ADULT; AGE FACTORS; AGED; BLOOD PRESSURE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; FEMALE; HETEROZYGOTE; HUMANS; HYPERTENSION; MIDDLE AGED; MUTATION; PILOT PROJECTS;

EID: 9644284307     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000145901.81989.46     Document Type: Article

References (30)

1. Lieberman J, Rodbard. Low blood pressure in young adults with cystic fibrosis. Ann Int Med 1975;82:806-808.
2. Lieberman J, Kellog F. Evaluation of the sweat chloride assay in adults: use of pilocarpine iontophoresis. Am J Med Sci. 1963;246:537-549.
3. 508 cystic fibrosis. Pediatrics. 1996;97:524-528.
4. Super M, Heagerty AM, Irtiza -Ali A, Schwarz MJ, Roberts T, Corbett. Blood pressure and cystic fibrosis carriers Pediatr Pulmonol 1998;suppl 19:208.
5. Super M Schwarz MJ. Mutations of the cystic fibrosis gene in the population of north-west England. Eur J Pediatr. 1992;151:108-111.
6. Dillon M, Littler WA, Mee F, O'Brien ET, Petrie JC, de Swiet M. Blood Pressure Measurement: Recommendations of the British Hypertension Society. London: BMJ Publishing Group; 1997.
7. Super M, Schwarz MJ, Malone G, Roberts T, Haworth A, Dermody G Active cascade testing for carriers of cystic fibrosis gene BMJ. 1994;308:1462-1467.
8. Kiesewetter S, Macek M, Jr Davis C, Curristin SM, Chu C-S, Graham C, Shrimpton AE, Cashman SM, Tsui L-C, Mickle J, Amos J, Highsmith WE, Shuber A, Witt DR, Crystal RG, Cutting GR. A mutation in CFTR produces different phenotypes depending on chromosomal background. Nat Genet. 1993;5:274-278.
9. Hamilton LC. How robust is robust regression? Stata Tech Bull 1999;2:21-26. Reprinted in Stata Tech Bull Reprints 1991;1:169-175.
10. Hamilton LC. How robust is robust regression? Stata Tech Bull 1999;2:21-26. Reprinted in Stata Tech Bull Reprints 1991;1:169-175.
11. Hardy R, Kuh D, Lanenberg C, Wadsworth MEJ. Birthweight, childhood social class and change in adult blood pressure in the 1946 British birth cohort. Lancet. 2003;362:1178-1183.
12. Dong W, Primatesta P, Bost L Health Survey for England and Wales 1996. Accessed at http://www.archive.official-documents.co.uk/document/doh/survey96/ tab6-19.htm (Figures 6C, 6G, 6-4, 6-8).
13. Haslett, Chilvers ER, Boon NA, Colledge NR. Davidson's Principles and practice of medicine, 19th ed. Edinburgh: Churchill Livingstone; 2002:1219.
14. Genuth SM. The Endocrine System. In: Berne M, Levy MN, Koeppen BM, Stanton BA, eds. Physiology, 5th ed. St. Louis: Mosby; 2004:946.
15. Lifton RP. Molecular genetics of human blood pressure variation. Science. 1996;272:676-680.
16. Donckerwolcke RA, Van Diemen-Steenvoorde R, van der Laag J, Koomans HA, Boer WR. Impaired diluting segment chloride reabsorption in patients with cystic fibrosis. Child Nephrol Urol. 1992;12:186-191.
17. Quinton PM Chloride impermeability in cystic fibrosis Nature. 1983;301:421-422.
18. - channel function. Nature. 1999;402:301-304.
19. Legris GJ, Dearborn D, Stern R, Geiss CL, Hopfer U, Douglas JG, Doershuk CF. Sodium space and intravascular volume:dietary sodium effects in cystic fibrosis and healthy adolescent subjects. Pediatrics. 1998;101:48-56.
20. Williams GW. Genetic factors associated with volume sensitive hypertension. Molecular and Cellular Endocrinology. 2004;217:41-44.
21. Quintero-Acenzio J, Vasquez-Leon M, Pino-Quintero LM. Association of sweat sodium with arterial blood pressure. N Engl J Med. 1966;274:1224-1228.
22. Levi J, Rosenfeld LB, Hansel Z, Elian E. Relationship of sweat sodium concentration to blood pressure in control subjects and in patients with essential and renal hypertension. Isr J Med Sci. 1970;6:665-668.
23. Naren AP, Cobb B, Li C, Roy K, Nelson D, Heda GD, Liao J, Kirk KL, Sorcher EJ, Hanrahan J, Clancy JP. A macromolecular complex of β adrenergic receptor, CFTR, and Ezrin/radixin/moesin-binding phosphoprotein 50 is regulated by PKA. PNAS. 2003;100:342-346.
24. De Lemos JA, McGuire D, Drazier MH B. B-type natiuretic peptide in cardiovascular disease. Lancet. 2003;362:316-322.
25. Kulaksiz H, Schmid A, Honscheid M, Eissels R, Klempnauer J, Cetlin Y. Guanylin in the human pancreas: a novel luminocrine regulatory pathway of electrolyte secretion via cGMP and CFTR in the ductal system. Histochem Cell Biol. 2001;115:131-145.
26. Warlow C, Sudlow C, Dennis M, Wardlaw J. Sanderxcock C. Stroke. Lancet. 2003;362:1211-1214.
27. INTERSALT Cooperative Research Group. Intersalt: An International Study of Electrolyte Excretion and Blood Pressure. Results for 24 hour Urinary Sodium and Potassium Excretion. BMJ. 1988;297:319-328.
28. Macek M Jr Macek M Sr Krebsova A, Nash E, Hamosh A, Reis A, Varon-Mateeva R, Schmidtke J, Maestri NE, Sperling K, Krawczak M, Cutting GR. Possible association of the allele status of CS. 7/Hhal polymorphism 5′ of the CFTR gene with postnatal female survival. Hum Genet. 1997;99:565-572.
29. Witt M, Erickson RP, Ober C, Howatt WF Farber R. Correlation of phenotypic and genetic heterogeneity in cystic fibrosis: variability in sweat electrolyte levels contributes to heterogeneity and is increased with the XV-2C/KM19 B haplotype. Am J Med Genet. 1991;39:137-143.
30. Super M. CFTR and disease implication for drug development. Lancet. 2000;355:1840-1842.